GlassScriptPhysician profile
Jean D Dib
NPI 1477556686
$22,985.41
in general payments reported to CMS, 2019-2025
61 companies · $3,757 in 2025
The $3,757 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,867 · 2020: $1,699 · 2021: $2,875 · 2022: $3,337 · 2023: $3,872 · 2024: $3,579 · 2025: $3,757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,207.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,779.00 | 2019-2025 | Vraylar, Qulipta, Linzess |
| Astrazeneca Pharmaceuticals LP | $2,504.47 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $1,852.14 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,799.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,156.74 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $983.28 | 2019-2025 | Jardiance, Tradjenta, Ofev |
| Glaxosmithkline, LLC. | $865.36 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Merck Sharp & Dohme LLC | $719.92 | 2019-2025 | Verquvo, Steglatro, Gardasil 9 |
| Amarin Pharma, INC. | $695.47 | 2019-2023 | |
| Axsome Therapeutics, INC. | $669.85 | 2023-2025 | Auvelity, Symbravo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $660.75 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $634.52 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $500.57 | 2019-2022 | |
| Allergan, INC. | $482.63 | 2019-2020 | |
| Abbott Laboratories | $453.92 | 2021-2025 | Freestyle Libre 3 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Dib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.